All In Biotech

Drug Trial Radar · NCT04429087

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

A First-In-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Administered by Parenteral Route in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

306

Actual

Start

Jul 29, 2020

Primary completion

Aug 31, 2026

Study completion Oct 1, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jun 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out the highest dose of obrixtamig and the best treatment schedule that people can tolerate. Obrixtamig is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. In this study, obrixtamig is given to people for the first time. Interim clinical data are available for obrixtamig. Participants get obrixtamig either weekly or once every 3 weeks. If there is benefit for the participants and if they can tolerate it, the treatment is given for a maximum of 3 years. During this time, participants visit the study site about 20 times depending on the response to the treatment. Doctors record any unwanted effects and regularly check the general health of the participants.

Conditions

  • Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Interventions

  • Obrixtamig - parenteral 1Drug

    Obrixtamig - parenteral 1

  • Obrixtamig - parenteral 2Drug

    Obrixtamig - parenteral 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arm 1 and Arm 2: Maximum tolerated dose (MTD)Time frame: up to 36 months
  2. Arm 1 and Arm 2: Number of patients with DLTs in the MTD evaluation periodTime frame: up to 36 months

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • Winship Cancer Institute

    Atlanta, Georgia

  • University of Maryland School of Medicine

    Baltimore, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Universitätsklinikum Köln (AöR)

    Cologne, Germany

  • Technische Universität Dresden

    Dresden, Germany

  • Universitätsklinikum Würzburg AÖR

    Würzburg, Germany

  • National Cancer Center Hospital East

    Chiba, Kashiwa, Japan

  • Hospital del Mar

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Clínica Universidad de Navarra

    Pamplona, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.